Medpal AI Regulatory News (MPAL)

20 March 2026

MedPal AI Plc

("MedPal AI" or the "Company")

Placing and WRAP Retail Offer

MedPal AI (AIM: MPAL, FRA: Z1N) the UK digital health and AI company, is pleased to announce that it has conditionally raised approximately £527,000 ("Placing") by way of the issue of 21,080,000 new ordinary shares ("Placing Shares") at a price of 2.5 pence per share ("Placing Price"). The Placing Price represents a 13% discount to the closing mid-price of the Company's ordinary shares on 19 March 2026.

The Company is also offering new ordinary shares to investors via a WRAP retail offer, which will be announced separately.

The proceeds from the Placing and the WRAP retail offer (together the "Fundraise") will be used to provide working capital for the Company's pharmacy operations to enable it to carry both higher levels and a wider range of stock to meet rising customer demand and also to fund a digital marketing campaign for MedPal.clinic.

The Placing is conditional on the Placing Shares, which will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, being admitted to trading on AIM ("Admission"). Admission of the Placing Shares is expected to occur on or around 26 March 2026.

For the avoidance of doubt, the WRAP retail offer is not part of the Placing. Completion of the WRAP retail offer is conditional, inter alia, upon the completion of the Placing but completion of the Placing is not conditional on the completion of the WRAP retail offer.

Total voting rights

Immediately following Admission and excluding any shares to be issued subject to the WRAP, the Company will have 476,234,640 Ordinary Shares in issue. Accordingly, the total number of Ordinary Shares in the Company with voting rights will be 476,234,640. This figure may be used by shareholders in the Company as denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Further information on the Company can be found on its website at www.medpalplc.com

The Company's LEI is 984500EDP8B0A14CBA61.

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.